Malarial dihydrofolate reductase as a paradigm for drug development against a resistance-compromised target

Abstract excerpt

Malarial dihydrofolate reductase (DHFR) is the target of antifolate antimalarial drugs such as pyrimethamine and cycloguanil, the clinical efficacy of which have been compromised by resistance arising through mutations at various sites on the enzyme. Here, we describe the use of cocrystal structures with inhibitors and substrates, along with efficacy and pharmacokinetic profiling for the design, characterization,...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Malaria Research and Control
• Share to Mosquito-borne diseases and control
• Share to Trypanosoma species research and implications